FocalTherics Partners with MellingMedical to Expand Prostate Cancer Treatment for Veterans
Event summary
- FocalTherics has partnered with MellingMedical to expand access to Focal One Robotic HIFU for Veterans with prostate cancer.
- The agreement allows federal healthcare providers to acquire Focal One through MellingMedical's VA Federal Supply Schedule.
- Nearly 500,000 Veterans are currently receiving prostate cancer treatment within the Veterans Healthcare System.
- The partnership aligns with the 2022 Cleland-Dole Act, which directed the VA to advance comprehensive prostate cancer care for Veterans.
The big picture
This partnership underscores the growing focus on advanced, minimally invasive treatments for prostate cancer within the Veterans Healthcare System. With Veterans diagnosed at twice the rate of the general population, the agreement aligns with broader federal initiatives to improve cancer care for military personnel. The deal also highlights the strategic importance of leveraging SDVOSBs to enhance healthcare access for Veterans.
What we're watching
- Adoption Pace
- How quickly federal healthcare facilities will adopt Focal One Robotic HIFU through the VA Federal Supply Schedule.
- Revenue Impact
- Whether the partnership will significantly boost FocalTherics' revenue given the scale of the Veterans Healthcare System.
- Regulatory Dynamics
- The extent to which government budgeting and procurement policies may affect the rollout of the technology.
Related topics